All In Biotech

Drug Trial Radar · NCT05756322

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 20, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Lin BioScience, IncIndustry
Sponsor type
Industry
Collaborators
Lin BioScience Pty Ltd
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages. The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.

Conditions

  • Relapsed or Resistant Acute Leukaemias

Interventions

  • LBS-007Drug

    Open Label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number, severity and duration of adverse events (AEs) and treatment-related AEs according to Common Terminology Criteria for Adverse Events (CTCAE) v5.Time frame: From baseline through 28 days after end of last treatment cycle (up to 12 months)
  2. Recommended Phase 2 Dose (RP2D) of LBS-007 in the subject population.Time frame: From baseline through 28 days after end of last treatment cycle (up to 12 months)

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois · Not yet recruiting

  • The University of Kansas Hospital

    Fairway, Kansas · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland · Recruiting

  • UNC Hospitals, The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Wollongong Private Hospital

    Wollongong, New South Wales, Australia · Completed

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Completed

  • The Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Active not recruiting

  • Hollywood Private Hospital

    Nedlands, Washington, Australia · Withdrawn

  • Q Medical Conselling

    Perth, Washington, Australia · Withdrawn

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • Jining No.1 People's Hospital

    Jining, Shandong, China · Recruiting

  • China Medical University Hospital

    Taichung, Taiwan · Not yet recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Not yet recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.